Safety Verification Trials of mFOLFIRI and Sequential IRIS + Bevacizumab as First- or Second-Line Therapies for Metastatic Colorectal Cancer in Japanese Patients

Shunsuke Kato,Hideaki Andoh,Makio Gamoh,Takuhiro Yamaguchi,Yasuko Murakawa,Hideki Shimodaira,Shin Takahashi,Takahiro Mori,Hisatsugu Ohori,Shun'ichi Maeda,Takao Suzuki,Satoshi Kato,Shoko Akiyama,Yuka Sasaki,Takashi Yoshioka,Chikashi Ishioka

Safety Verification Trials of mFOLFIRI and Sequential IRIS + Bevacizumab as First- or Second-Line Therapies for Metastatic Colorectal Cancer in Japanese Patients

2012

Shunsuke Kato
Hideaki Andoh
Makio Gamoh
Takuhiro Yamaguchi
Yasuko Murakawa
Hideki Shimodaira
Shin Takahashi
Takahiro Mori
Hisatsugu Ohori
Shun'ichi Maeda
Takao Suzuki
Satoshi Kato
Shoko Akiyama
Yuka Sasaki
Takashi Yoshioka
Chikashi Ishioka

Objective: S-1 is effective in sequential combination with irinotecan (IRIS) in treating metastatic colorectal cancer. We conducted a randomized phase II trial of

Keywords:

Randomized controlled trial
Bevacizumab
Colorectal cancer
Progression-free survival
Medicine
Irinotecan
General surgery
Confidence interval
Clinical endpoint
Oncology
second line
Fluorouracil
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations